Genzyme says it is now shipping the drug Fabrazyme from its newly approved Framingham manufacturing plant, resolving shortages created by manufacturing problems last year.
Fabrazyme is used to treat Fabry’s disease, a rare and serious condition.
The new supply allows all patients in the U.S. to begin full dosing this month, and new U.S. patients can begin treatment at full levels, the company said.
Genzyme, a subsidiary of French drug maker Sanofi, said it’s still clearing up shortages of the drug elsewhere in the world. In Europe, it said, patients with the most severe cases of the disease are moving to full dosages of the drug this month. Globally, supply levels will continue to return to normal over the year as various regulatory hurdles are cleared, the company said.
